Randomized Double Blind (Sponsor Unblind) Study Evaluating the Effect of 14 Days of Treatment With Danirixin (GSK1325756) on Neutrophil Extracellular Traps (NETs) Formation in Participants With Stable Chronic Obstructive Pulmonary Disease (COPD)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Oct 2017
At a glance
- Drugs Danirixin (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 03 Oct 2017 Planned End Date changed from 7 Jun 2018 to 10 Jul 2018.
- 03 Oct 2017 Planned primary completion date changed from 7 Jun 2018 to 10 Jul 2018.
- 03 Oct 2017 Planned initiation date changed from 3 Oct 2017 to 3 Nov 2017.